A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése: Magyar konszenzusajánlás

Translated title of the contribution: Diagnosis and treatment of chronic hepatitis B and D

Horváth Gábor, Gerlei Zsuzsanna, Gervain Judit, G. Lengyel, Makara Mihály, A. Pár, Rókusz László, F. Szalay, Tornai István, Werling Klára, B. Hunyady

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

Original languageHungarian
Pages (from-to)23-35
Number of pages13
JournalOrvosi Hetilap
Volume158
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Chronic Hepatitis D
Chronic Hepatitis B
Therapeutics
Lamivudine
Tenofovir
Infection
Interferons
Hepatitis D
Guidelines
Elasticity Imaging Techniques
Costs and Cost Analysis
Immunosuppressive Agents
Hepatitis B Surface Antigens
Life Expectancy
Nucleic Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése : Magyar konszenzusajánlás. / Gábor, Horváth; Zsuzsanna, Gerlei; Judit, Gervain; Lengyel, G.; Mihály, Makara; Pár, A.; László, Rókusz; Szalay, F.; István, Tornai; Klára, Werling; Hunyady, B.

In: Orvosi Hetilap, Vol. 158, 01.02.2017, p. 23-35.

Research output: Contribution to journalArticle

Gábor, Horváth ; Zsuzsanna, Gerlei ; Judit, Gervain ; Lengyel, G. ; Mihály, Makara ; Pár, A. ; László, Rókusz ; Szalay, F. ; István, Tornai ; Klára, Werling ; Hunyady, B. / A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése : Magyar konszenzusajánlás. In: Orvosi Hetilap. 2017 ; Vol. 158. pp. 23-35.
@article{55fae9bf748e4c5a9899ace3c83c926b,
title = "A hepatitis B- {\'e}s D-v{\'i}rus-fertoz{\'e}s diagnosztik{\'a}ja, antivir{\'a}lis kezel{\'e}se: Magyar konszenzusaj{\'a}nl{\'a}s",
abstract = "Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0.5-0.7{\%}. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.",
keywords = "Adefovir, Cirrhosis, Entecavir, Hepatitis B virus, Hepatitis D virus, Interferon, Lamivudine, Liver cancer, Pegylated interferon, Tenofovir, Viral hepatitis",
author = "Horv{\'a}th G{\'a}bor and Gerlei Zsuzsanna and Gervain Judit and G. Lengyel and Makara Mih{\'a}ly and A. P{\'a}r and R{\'o}kusz L{\'a}szl{\'o} and F. Szalay and Tornai Istv{\'a}n and Werling Kl{\'a}ra and B. Hunyady",
year = "2017",
month = "2",
day = "1",
doi = "10.1556/650.2017.30689",
language = "Hungarian",
volume = "158",
pages = "23--35",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",

}

TY - JOUR

T1 - A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése

T2 - Magyar konszenzusajánlás

AU - Gábor, Horváth

AU - Zsuzsanna, Gerlei

AU - Judit, Gervain

AU - Lengyel, G.

AU - Mihály, Makara

AU - Pár, A.

AU - László, Rókusz

AU - Szalay, F.

AU - István, Tornai

AU - Klára, Werling

AU - Hunyady, B.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

AB - Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

KW - Adefovir

KW - Cirrhosis

KW - Entecavir

KW - Hepatitis B virus

KW - Hepatitis D virus

KW - Interferon

KW - Lamivudine

KW - Liver cancer

KW - Pegylated interferon

KW - Tenofovir

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85014291384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014291384&partnerID=8YFLogxK

U2 - 10.1556/650.2017.30689

DO - 10.1556/650.2017.30689

M3 - Article

C2 - 28218868

AN - SCOPUS:85014291384

VL - 158

SP - 23

EP - 35

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

ER -